Module 19 2021
28/05/2021
Follow-on (2 nd generation) CDx
• CDx claiming to be equivalent to a CE-marked CDx (same population, specimen, drug, etc.) • Expected to select the same population for which efficacy and safety were demonstrated for corresponding drug in pivotal trial(s) • Bridging data may be used to demonstrate clinical performance • In lieu of new (interventional) clinical data • Use samples that are relevant and representative • Equivalence criteria should be pre-specified • Ensure that analytical validation is finalised prior to bridging • Devices authority needs to be notified of CDx bridging studies using left-over samples (no authorisation needed)
The Organisation for Professionals in Regulatory Affairs
25
Future UK IVD regulation
• MHRA is working to develop a robust, world-leading regulatory regime for medical devices that prioritises patient safety - to be in place from July 2023. • We are considering international standards and global harmonisation • We will engage with life sciences and healthcare sector stakeholders • We are identifying and prioritising elements of international best practice that promote public health and patient safety. • We plan to have a formal public consultation on future medical device regulation in Summer 2021 • We are keen to build on a range of expertise – please look out for more information and opportunities to engage on this topic on gov.uk in future.
The Organisation for Professionals in Regulatory Affairs
26
13
Made with FlippingBook flipbook maker